KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 113 filers reported holding KALVISTA PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.54 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,613,467 | +48.3% | 582,905 | +38.6% | 0.00% | +100.0% |
| Q2 2023 | $3,784,862 | +103.8% | 420,536 | +78.0% | 0.00% | 0.0% |
| Q1 2023 | $1,856,898 | +104044.6% | 236,267 | -10.5% | 0.00% | 0.0% |
| Q4 2022 | $1,783 | -100.0% | 263,867 | -21.5% | 0.00% | -50.0% |
| Q3 2022 | $4,876,000 | +87.3% | 336,118 | +27.1% | 0.00% | +100.0% |
| Q2 2022 | $2,603,000 | +133.7% | 264,478 | +250.1% | 0.00% | – |
| Q1 2022 | $1,114,000 | -50.0% | 75,552 | -55.1% | 0.00% | -100.0% |
| Q4 2021 | $2,227,000 | -25.0% | 168,331 | -1.1% | 0.00% | 0.0% |
| Q3 2021 | $2,970,000 | -27.2% | 170,208 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $4,078,000 | -30.6% | 170,208 | -25.6% | 0.00% | -50.0% |
| Q1 2021 | $5,873,000 | +49.7% | 228,625 | +10.7% | 0.00% | +100.0% |
| Q4 2020 | $3,922,000 | +58.8% | 206,517 | +5.3% | 0.00% | 0.0% |
| Q3 2020 | $2,470,000 | +5.1% | 196,181 | +1.0% | 0.00% | 0.0% |
| Q2 2020 | $2,350,000 | +81.9% | 194,181 | +15.0% | 0.00% | 0.0% |
| Q1 2020 | $1,292,000 | -39.9% | 168,842 | +39.8% | 0.00% | 0.0% |
| Q4 2019 | $2,151,000 | +44.3% | 120,808 | -6.0% | 0.00% | 0.0% |
| Q3 2019 | $1,491,000 | -39.7% | 128,490 | +15.1% | 0.00% | 0.0% |
| Q2 2019 | $2,473,000 | +19.1% | 111,630 | +53.9% | 0.00% | 0.0% |
| Q1 2019 | $2,076,000 | +843.6% | 72,547 | +551.6% | 0.00% | – |
| Q4 2018 | $220,000 | -19.7% | 11,133 | -10.1% | 0.00% | – |
| Q3 2018 | $274,000 | – | 12,383 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |